Zheng Fang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zheng Fang has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- An-Yi Chang
Aiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California San Diego, La Jolla, USA
2 shared publications - Joseph Wang
University of California San Diego
2 shared publications Lei Sun
Aiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California San Diego, La Jolla, CA 92093, USA
2 shared publications- Liangfang Zhang
University of California San Diego
2 shared publications - Ronnie H. Fang
Aiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California San Diego, La Jolla, USA
2 shared publications - Shichao Ding
Key Laboratory of 3D Micro/Nano Fabrication and Characterization of Zhejiang Province School of Engineering Westlake University Hangzhou China
2 shared publications
Latest Publications
- Open Access
- 11 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (28) , eadw8578
Picoeukaryote-based biohybrid microrobots for active delivery in the kidney
Confined spaces in the human body pose substantial challenges for biomedical procedures. Navigating these ultrasmall environments is essential for precise drug delivery, improving treatment outcomes and reducing adverse effects. Microrobots offer a promising approach to accessing these complex microenvironments. Here, we show a biohybrid microrobot based on picoeukaryotes, engineered as a cargo carrier for active delivery in tight in vivo spaces. The microrobot exhibits strong in vitro motility through narrow two-dimensional and complex three-dimensional networks and, in vivo, achieves outstanding kidney penetration, uniform distribution, and >48-hour retention while resisting flow shear and immune clearance, with excellent biosafety. Their ability to retain functionality and sustain propulsion within the confined and complex kidney vasculatures and interstitial spaces underscore their potential for long-term, active delivery in confined biological environments. The picoeukaryote-based biohybrid microrobot system represents a major advancement in active drug delivery, especially tailored to the challenging microenvironments of the kidney.
- 11 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (28) , eadw8578
Open AccessPicoeukaryote-based biohybrid microrobots for active delivery in the kidney
Confined spaces in the human body pose substantial challenges for biomedical procedures. Navigating these ultrasmall environments is essential for precise drug delivery, improving treatment outcomes and reducing adverse effects. Microrobots offer a promising approach to accessing these complex microenvironments. Here, we show a biohybrid microrobot based on picoeukaryotes, engineered as a cargo carrier for active delivery in tight in vivo spaces. The microrobot exhibits strong in vitro motility through narrow two-dimensional and complex three-dimensional networks and, in vivo, achieves outstanding kidney penetration, uniform distribution, and >48-hour retention while resisting flow shear and immune clearance, with excellent biosafety. Their ability to retain functionality and sustain propulsion within the confined and complex kidney vasculatures and interstitial spaces underscore their potential for long-term, active delivery in confined biological environments. The picoeukaryote-based biohybrid microrobot system represents a major advancement in active drug delivery, especially tailored to the challenging microenvironments of the kidney.
- Top Cited PapersOpen Access
- 14 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-13
Inhalable biohybrid microrobots: a non-invasive approach for lung treatment
Amidst the rising prevalence of respiratory diseases, the importance of effective lung treatment modalities is more critical than ever. However, current drug delivery systems face significant limitations that impede their efficacy and therapeutic outcome. Biohybrid microrobots have shown considerable promise for active in vivo drug delivery, especially for pulmonary applications via intratracheal routes. However, the invasive nature of intratracheal administration poses barriers to its clinical translation. Herein, we report on an efficient non-invasive inhalation-based method of delivering microrobots to the lungs. A nebulizer is employed to encapsulate picoeukaryote algae microrobots within small aerosol particles, enabling them to reach the lower respiratory tract. Post nebulization, the microrobots retain their motility (~55 μm s-1) to help achieve a homogeneous lung distribution and long-term retention exceeding five days in the lungs. Therapeutic efficacy is demonstrated in a mouse model of acute methicillin-resistant Staphylococcus aureus pneumonia using this pulmonary inhalation approach to deliver microrobots functionalized with platelet membrane-coated polymeric nanoparticles loaded with vancomycin. These promising findings underscore the benefits of inhalable biohybrid microrobots in a setting that does not require anesthesia, highlighting the substantial translational potential of this delivery system for routine clinical applications.
- 14 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-13
Top Cited PapersOpen AccessInhalable biohybrid microrobots: a non-invasive approach for lung treatment
Amidst the rising prevalence of respiratory diseases, the importance of effective lung treatment modalities is more critical than ever. However, current drug delivery systems face significant limitations that impede their efficacy and therapeutic outcome. Biohybrid microrobots have shown considerable promise for active in vivo drug delivery, especially for pulmonary applications via intratracheal routes. However, the invasive nature of intratracheal administration poses barriers to its clinical translation. Herein, we report on an efficient non-invasive inhalation-based method of delivering microrobots to the lungs. A nebulizer is employed to encapsulate picoeukaryote algae microrobots within small aerosol particles, enabling them to reach the lower respiratory tract. Post nebulization, the microrobots retain their motility (~55 μm s-1) to help achieve a homogeneous lung distribution and long-term retention exceeding five days in the lungs. Therapeutic efficacy is demonstrated in a mouse model of acute methicillin-resistant Staphylococcus aureus pneumonia using this pulmonary inhalation approach to deliver microrobots functionalized with platelet membrane-coated polymeric nanoparticles loaded with vancomycin. These promising findings underscore the benefits of inhalable biohybrid microrobots in a setting that does not require anesthesia, highlighting the substantial translational potential of this delivery system for routine clinical applications.